| Yi Fumei,Wang Hao,Yuan Huishu,Li Jinna,Jiang Yuliang,Tian Suqing,Wang Junjie*.CT-guided 125I radioactive seed implantation for locally recurrent rectal cancer[J].Chinese Journal of Radiological Medicine and Protection,2014,34(1):30-33 |
| CT-guided 125I radioactive seed implantation for locally recurrent rectal cancer |
| Received:February 19, 2013 |
| DOI：10.3760/cma.j.issn.0254-5098.2014.01.008 |
| KeyWords:Rectal cancer Local recurrence Radioactive seed Efficacy |
| FundProject:国家自然科学基金（81071834） |
| Author Name | Affiliation | E-mail | | Yi Fumei | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Wang Hao | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Yuan Huishu | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Li Jinna | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Jiang Yuliang | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Tian Suqing | Cancer Center, Peking University Third Hospital, Beijing 100191, China | | | Wang Junjie* | Cancer Center, Peking University Third Hospital, Beijing 100191, China | junjiewang_edu@sina.cn |
|
| Hits: 3811 |
| Download times: 2474 |
| Abstract:: |
| Objective To evaluate the efficacy and adverse reactions of CT-guided 125I radioactive seed implantation in treatment of locally recurrent rectal cancer (LRRC). Methods Thirty patients with LRRC who refused operation or were unable to endure pelvic radiotherapy received 125I seed implantation under CT guidance. Three-dimensional treatment planning system was used to calculate the number, activity, and dose of the seeds needed. The activity of seeds ranged from 14.8 to 29.6 MBq with a median of 25.9 MBq, the seed numbers ranged from 33 to 137 with a median of 74.5, the prescription doses ranged from 120-160 Gy,and the actual verification dose D90 ranged from 75.91 to 159.32 Gy with a median of 119.77 Gy. Dosimetric verification by CT scanning was conducted immediately after the treatment. Follow-up was conducted for 15.2 months(4.2-35.0 months). Results The follow-up rate was 93.3%. The pain relief rate was 95.2%. The overall response rate was 50.0%, including a complete response rate of 13.3% and a partial response rate of 36.7%. The 1-and 2-year local control rates were 30.0% and 8.0% respectively. The median local control survival time was 7.8 month. The 1-and 2-year survival rates were 66.5% and 32.9% respectively. The median overall survival time was 21.5 months. Complications, mainly adverse effects of skin and urinary system (frequent urination, urgent urination, and dysuria) occurred in 6 patients with a rate of 20.0%. Conclusions Minimally invasive and with satisfying efficacy and tolerable complications, CT-guided 125I radioactive seed implantation is a favorable option for treatment of LRRC, especially for the patients who have undergone previous pelvic radiation. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
